Efficacy and safety of ceftazidime-avibactam versus tigecycline in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae
Tongfei Yang, Mao Xu, Lu Cao, Yaling Shi, Xianpeng Shi · 2026
Read Efficacy and safety of ceftazidime-avibactam versus tigecycline in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae by Tongfei Yang, Mao Xu, Lu Cao, Yaling Shi, Xianpeng Shi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13561761.txt.
Description
Tongfei Yang and co-authors present a 2026 study on two drug plans for severe lung infection. The infection is caused by a germ that resists a key drug class. Both plans are used in hospitals, but head-to-head proof was thin. The team looked back at 63 patients treated at one Chinese hospital from 2023 to 2025.
One plan cleared the germ from far more patients than the other. Rates of cure and death were much the same in both groups. Blood clotting problems and low platelet counts were more common on the second plan. Older age and diabetes linked to higher death odds. The authors offer the results as a guide for drug choice in this hard infection.
Catalog record
| CREATOR | Tongfei Yang, Mao Xu, Lu Cao, Yaling Shi, Xianpeng Shi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |